Mauriello J A, Aljian J
Department of Ophthalmology, University of Medicine and Dentistry of New Jersey, Medical School, Newark 07107.
Br J Ophthalmol. 1991 Dec;75(12):737-9. doi: 10.1136/bjo.75.12.737.
To determine the long-term efficacy of botulinum toxin injections for the treatment of facial dyskinesias we studied 50 consecutive patients with blepharospasm, hemifacial spasm, and Meige syndrome. All received their first injection between September 1983 and June 1984. A total of 520 injections were given; the average number of injections per patient was 10.4 over the seven-year period ending September 1990. Twenty-six (52%) of the patients continued to return for periodic injections, while three patients no longer receive injections since they failed to respond adequately to treatment. Three patients with blepharospasm were in remission and required no further treatment, after a series of six, four, and three injections. Six patients were treated until they died of causes unrelated to facial dyskinesia or its treatment. Six patients are still being treated elsewhere because they could obtain injections closer to their homes. Five of the original 50 patients have been lost to follow-up. A patient with hemifacial spasm had one injection with good result but was not sufficiently bothered by her disease to return for reinjection. Complications were transient, minimal, well tolerated, and did not increase with increased number of injections.
为了确定肉毒杆菌毒素注射治疗面部运动障碍的长期疗效，我们研究了50例连续性眼睑痉挛、半面痉挛和梅杰综合征患者。所有患者均在1983年9月至1984年6月期间接受了首次注射。共进行了520次注射；截至1990年9月的七年期间，每位患者平均注射次数为10.4次。26例（52%）患者继续定期回来接受注射，而3例患者因对治疗反应不佳不再接受注射。3例眼睑痉挛患者在分别接受了6次、4次和3次注射后病情缓解，无需进一步治疗。6例患者一直接受治疗，直至死于与面部运动障碍或其治疗无关的原因。6例患者仍在其他地方接受治疗，因为在离家更近的地方可以获得注射。最初的50例患者中有5例失访。1例半面痉挛患者注射1次后效果良好，但病情未严重到令其回来再次注射。并发症是短暂的、轻微的，耐受性良好，且不会随着注射次数的增加而增多。
